RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Quintiles today announced that it has completed the previously
announced acquisition of Novella
Clinical (Novella), a full-service clinical research organization
(CRO) focused primarily on emerging oncology customers as well as those
in the medical device and diagnostics sectors.
“We are extremely pleased to have completed the acquisition of Novella
and look forward to working together to increase our collective
opportunities with emerging oncology and medical device companies,” said
Paula Brown Stafford
, president, Clinical Development at Quintiles.
“With the transaction now officially closed, we will focus our efforts
on leveraging Quintiles’ global resources and capabilities with the
expertise and personal attention of Novella to continue to deliver the
high-quality services customers have come to expect from both companies.”
Now known as “Novella Clinical, a Quintiles company,” Novella will
operate as a unit within Quintiles, retaining its existing leadership
team as well as its specialized customer focus.
About Quintiles
Quintiles (NYSE:Q) is the world’s largest provider of biopharmaceutical
development and commercial outsourcing services with a network of more
than 27,000 employees conducting business in approximately 100
countries. We have helped develop or commercialize all of the top-50
best-selling drugs on the market. Quintiles applies the breadth and
depth of our service offerings along with extensive therapeutic,
scientific and analytics expertise to help our customers navigate an
increasingly complex healthcare environment as they seek to improve
efficiency and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit www.quintiles.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Such forward-looking statements
reflect, among other things, Quintiles’ current expectations and
anticipated results of operations, all of which are subject to known and
unknown risks, uncertainties and other factors that may cause Quintiles’
actual results, performance or achievements, market trends, or industry
results to differ materially from those expressed or implied by such
forward-looking statements. Therefore, any statements contained herein
that are not statements of historical fact may be forward-looking
statements and should be evaluated as such. Without limiting the
foregoing, the words “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “may,” “plans,” “projects,” “should,” “targets,” “will” and
the negative thereof and similar words and expressions are intended to
identify forward-looking statements.
These statements are subject to risks, uncertainties and assumptions,
including our ability to complete, integrate and achieve our intended
objectives with respect to the proposed acquisition of Novella Clinical
and those described under the section entitled "Risk Factors" in
Quintiles’ prospectus dated May 8, 2013, filed with the SEC pursuant to
Rule 424(b) of the Securities Act on May 9, 2013, as such factors may be
updated from time to time in Quintiles’ periodic filings with the SEC,
which are accessible on the SEC's website at www.sec.gov.
These factors should not be construed as exhaustive and should be read
in conjunction with the other cautionary statements that are included in
this release and in Quintiles’ filings with the SEC. Unless legally
required, Quintiles assumes no obligation to update any such
forward-looking information to reflect actual results or changes in the
factors affecting such forward-looking information.
Click here
to subscribe to Mobile Alerts for Quintiles.
Source: Quintiles